Published online before print April 22, 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
* Musculoskeletal Research Group,
Hematological Sciences, and
Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
2Correspondence: Musculoskeletal Research Group, Institute of Cellular Medicine, 4th Floor Catherine Cookson Building, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. E-mail: catharien.hilkens{at}newcastle.ac.uk
Promising immunotherapeutic tools for T cell-mediated pathologies are alternatively activated dendritic cells (aaDC), which exert their effect through the regulation and tolerization of T cells. As naïve and memory T cells have different susceptibilities to tolerogenic signals, it is important to understand the modulatory effects of aaDC on these T cell subsets. We have examined regulation of naïve and memory CD4+ T cells by human aaDC generated with dexamethasone, the active form of vitamin D3, 1
,25-dihydroxyvitamin D3, and LPS. Although aaDC induced low, primary, allogeneic responses by naïve and memory T cells, aaDC regulated the differentiation of these T cell subsets in a distinct manner. Naïve T cells primed by aaDC retained a strong, proliferative capacity upon restimulation but were skewed toward a low IFN-
/high IL-10 cytokine profile. In contrast, memory T cells primed by aaDC became hyporesponsive in terms of proliferation and cytokine production. Induction of anergy in memory T cells by aaDC was not a result of the presence of CD25hi regulatory T cells and could be partially reversed by IL-2. Both T cell subsets acquired regulatory activity and inhibited primary CD4 and CD8 responses. Addition of exogenous IL-12p70 during T cell priming by aaDC prevented anergy induction in memory T cells and cytokine polarization in naïve T cells, indicating that the lack of IL-12p70 is a key feature of aaDC. Our finding that aaDC differentially regulate naïve and memory T cells is important for understanding and maximizing the therapeutic potential of aaDC.
Key Words: tolerance • cytokine deviation • hyporesponsiveness • immunotherapy
This article has been cited by other articles:
 |
|
 |
|
  C Ward, K Eger, J Diboll, D Jones, M A Haniffa, M Brodlie, A Fisher, J L Lordan, P A Corris, and C M U Hilkens Bronchial epithelial cells cultured from clinically stable lung allograft patients promote the development of macrophages from monocytes rather than dendritic cells Thorax, May 1, 2009; 64(5): 430 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Lakey, T. G. Morgan, A. D. Rowan, J. D. Isaacs, T. E. Cawston, and C. M. U. Hilkens A novel paradigm for dendritic cells as effectors of cartilage destruction Rheumatology, May 1, 2009; 48(5): 502 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Anderson, D. J. Swan, B. L. Sayers, R. A. Harry, A. M. Patterson, A. von Delwig, J. H. Robinson, J. D. Isaacs, and C. M. U. Hilkens LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells J. Leukoc. Biol., February 1, 2009; 85(2): 243 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A W Thomson and P D Robbins Tolerogenic dendritic cells for autoimmune disease and transplantation Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii90 - iii96. [Abstract] [Full Text] [PDF]
|
|
